Oncology vs Metabolic — Deal Terms Comparison

Oncology Median Upfront

$258M

Total: $1.6B

Metabolic Median Upfront

$935M

Total: $4.5B

Oncology Royalties

11.8%-19.3%

Tiered to 23.3%

Metabolic Royalties

16.1%-29.5%

Tiered to 33.5%

Model Your Deal

Market Analysis

Oncology and Metabolic represent distinct licensing landscapes with different risk-reward dynamics. Phase 2 oncology deals carry a median total deal value of $1.6B with $258M upfront, compared to $4.5B total value and $935M upfront for metabolic. The differences reflect divergent clinical development timelines, regulatory pathways, and addressable market sizes.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

How do oncology and metabolic deal terms compare?

Oncology Phase 2 deals average $1.6B total value ($258M upfront), while Metabolic deals average $4.5B ($935M upfront). The differences are driven by addressable market size, clinical development complexity, and regulatory pathway characteristics.

Which therapeutic area commands higher royalty rates: Oncology or Metabolic?

Oncology base royalties range from 11.8% to 19.3%, while Metabolic royalties range from 16.1% to 29.5%. Royalty rates reflect pricing power, competitive dynamics, and patent protection characteristics specific to each therapeutic area.

What drives the deal value differences between oncology and metabolic?

Key factors include addressable patient population size, clinical trial costs and timelines, regulatory pathway complexity, pricing and reimbursement dynamics, and competitive landscape density. Oncology and Metabolic each have unique value drivers that shape deal economics.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Related Benchmarks

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Oncology Deal Overview

Metabolic Deal Overview

Phase 2 Deal Benchmarks

Ready to Calculate Your Deal Terms?

Need the full deal landscape?